All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @fxe3_jones on TikTok · 404s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @fxe3_jones's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00To work stank and ADHD be subsided with peptides and all pharmaceuticals in general, and is it worth it?
  2. 0:03That was a reply to one of my videos, I'm not allowed to comment underneath it, if you guys would like to comment more
  3. 0:06suggestions and questions you have about neuroscience, I'm all about answering them.
  4. 0:10Just before the video started, I'm reminding you that I'm not a psychiatrist, psychologist, and neuroscientist.
  5. 0:13This is just so I'm interested in, so don't take my advice, this is all for educational purposes.
  6. 0:17To grasp how peptides and pharmaceuticals could potentially even cure people of ADHD,
  7. 0:21we need to first understand what ADHD actually is.
  8. 0:24Now simply, we're individuals who have the neurodevelopmental condition,
  9. 0:28have less grey matter, particularly in the prefrontal cortex and hippocampus.
  10. 0:32E
  11. 0:51Diohexa binds to the HF and C-MAP receptor, it stimulates the action of the HF
  12. 1:01on its receptor C-MAP which is critical for nerve cell survival and synaptic plasticity.
  13. 1:06Now, Diohexa is not going to save you from all your issues, you need to be doing something that is
  14. 1:11outside of all of these distractions while you're taking it because it's one of those long-term
  15. 1:14potentiation peptides, meaning that the spice it grows, if you're doing things that are bad habits
  16. 1:21and distractions such as doing scrolling and going to phone, you're only going to strengthen
  17. 1:24those new connections more.
  18. 1:25If you're going to take Dioxxa in order to treat ADHD, you've got to be associating
  19. 1:28Dioxxa with complexity and things that need your prefrontal cortex and your can't just
  20. 1:33completely activate it and almost overclocking.
  21. 1:34You need it almost tiring your brain when you're doing Dioxxa in order for you to be
  22. 1:38kind of cured of your symptoms.
  23. 1:40And while it might not be a cure, you will notice that after it you'll probably be chasing
  24. 1:42complexity rather than just chasing simply scrolling your phone until you're punctured.
  25. 1:47All day.
  26. 1:48C-Max.
  27. 1:49You've probably heard it all before.
  28. 1:50These are all mainstream stuff so that people I don't have to go into intense detail to explain
  29. 1:53the mechanisms.
  30. 1:54C-Max increases the level and expression of BNF and its receptor TRKB in heavy campus.
  31. 1:58It also modulates serotonergic and dopaminergic systems in the brain.
  32. 2:02It's known to not affect cortisol levels, which is unlike traditional stimulants, which put
  33. 2:05a lot of stress on your sympathetic nervous system.
  34. 2:07Over riding blood pressure, that's the same reason why it decreases.
  35. 2:10Some people's life expectancy, you're taking ADHD meds for such a prolonged amount of time
  36. 2:13because you're always in a sympathetic nervous system state.
  37. 2:15And rather than traditional stimulants, which up regulate dopaminergic and no-renorphine
  38. 2:19systems are crazy, it just modulates them so it balances them out rather than just adding
  39. 2:22more or decreasing.
  40. 2:23Someone I knew took C-Max before they did their 11th prelims and it improved their memory
  41. 2:29like crazy and active recall.
  42. 2:30And they were taking it internationally so they were just doing two drops a day and that
  43. 2:35significantly improved their memory after recall and motivation.
  44. 2:37I remember telling me that you're almost studying an hour before the prelims and you
  45. 2:41somehow got an age and average over a day.
  46. 2:43Look, an age and crazy, but when you're studying an hour beforehand it's pretty alright.
  47. 2:46Now we're going to be covering pharmaceuticals.
  48. 2:49One of the personal I know right now is one for seeing.
  49. 2:51It was developed to treat high blood pressure, but it actually acts in the free frontal cortex
  50. 2:55as a selective nerve and apron and adero-siptor agonist strengthening neural network connectivity
  51. 3:00to improve working memory and pulse control and attention.
  52. 3:02It works post-synaptically to enhance signal to noise ratio, which I mentioned before
  53. 3:05is like one of the main issues in the pre-frontal cortex for people with ADHD, you struggle with
  54. 3:09that attention deficit disorder and that executive dysfunction, particularly under stress
  55. 3:14as well.
  56. 3:15It's in a way that it strengthens neural spines despite stress, which is like the main
  57. 3:18killer for the sciences.
  58. 3:20So unlike stimulants that increase nerve nerve nerve nerve in the release, one person mimics
  59. 3:24the beneficial effect of nerve nerve nerve on post-synaptic receptors.
  60. 3:27Increase of the firing of pre-frontal cortex cells, enhances focus and decreases distractibility
  61. 3:31without the stress on the sympathetic nervous system.
  62. 3:33It also acts in the peripheral nervous system to lower blood pressure, which is the sympathetic
  63. 3:36effect which I mentioned and promotes the growth of the maturation of the injury spines
  64. 3:38in the medial pre-frontal cortex.
  65. 3:39This is one I'm recommending.
  66. 3:40This is dexamethadamine or bibancin, the next one.
  67. 3:44These are both the ones saying that there's dexamethadamine, I'm currently on and so I
  68. 3:48have the best opportunity to ensure my strength.
  69. 3:50Flow-vancin increases levels of nerve nerve nerve nerve nerve and dopamine, which are typically
  70. 3:53imbalanced in individuals with ADHD.
  71. 3:54It improves performance by stimulating the release of these neurotransmitters, enhancing
  72. 3:57communication within circuits associated with reward, attention and executive dysfunction.
  73. 4:03Studies suggest it improves cognitive enhancing by effects.
  74. 4:08Studies suggest it improves cognitive enhancing effects by acting on receptors and pre-frontal cortex,
  75. 4:11which are decreasing in decreasing procrastination and strengthening prioritization skills.
  76. 4:16So there's my two points.
  77. 4:20This is both one-pacing and one-pacing.
  78. 4:23One's a decrease on sympathetic nervous system and one's an increase on sympathetic nervous
  79. 4:27system.
  80. 4:28But both work hand in hand in improving your circuits.
  81. 4:30For example, if you're someone who's all over the place very help, you're active and take
  82. 4:33stimulus.
  83. 4:34You might feel motivated, but you can get distracted very easily due to your executive dysfunction.
  84. 4:38If you take one-pacing or excite that though, you're regulating both stimulation and your
  85. 4:43physical jitters and all of these things and you're able to better grasp and control the
  86. 4:48aspects of that virus.
  87. 4:50This is why I recommend taking- if you're going to take pharmaceuticals, I recommend- this is
  88. 4:54why I'm saying if you're diagnosed with ADHD, I recommend talking to your psychiatrist about
  89. 4:58quaffacine and 5-hands as a mix.
  90. 5:00You take 1% at night and 5-hands in the morning after a meal.
  91. 5:03Studies have shown combining a stimulant like 5-hands we've been focusing can lead to better
  92. 5:06working memory improvements and overall ADHD-sink and control rather than medication alone.
  93. 5:09Last profile.
  94. 5:10The second one is to help me get the side effects of 5-hands such as irritability and anxiety
  95. 5:13and insomnia.
  96. 5:14Overall, this will strengthen your open-up work connections and make sure that the signal
  97. 5:20to noise ratio is improved significantly.
  98. 5:22The denture-expine, your executive function has improved because the quaffacine and the
  99. 5:26signal to noise ratio because the quaffacine is when you take 5-hands it's not even stimulating
  100. 5:29and rather your dopamine is directed in the right spot.
  101. 5:34Long-term change would likely be peptides because you're actually physically changing structures
  102. 5:38of your brain to prioritize these areas when you struggle it.
  103. 5:41While stimulants and pharmaceuticals are good at treating ADHD symptoms they don't
  104. 5:46fix the underlying issue which means once you're still taking all of your issues I can come
  105. 5:50back or even rebound worse than it was before but with things like C-Max and Dyehksa, Dyehksa's
  106. 5:58long-term potentiation.
  107. 5:59So whatever your network you create during that process and whatever you decide to reinforce
  108. 6:02which is your choice will stay with you for life which means if you use it in the right
  109. 6:06way you'll likely create complexity and hard work which might be something to struggle
  110. 6:10with same thing as C-Max.
  111. 6:11You're increasing beginner and particularly in the beginners which is working memory and
  112. 6:15modulating all of those different magic systems so that you don't feel the need to be, you
  113. 6:18don't have executive dysfunction, you're not going to distract it easily and it improves
  114. 6:21that overall long-term outcome.
  115. 6:24Thank you for listening.
  116. 6:27I didn't prepare any sort of speeches or anything of the sort so I hope this was complex enough
  117. 6:33for you instead of formal.
  118. 6:34Let me know if you guys have any feedback or suggestions.

Semax and selank for ADHD: what the brain peptide hype gets wrong

JonesX3

TikTok creator

4.4K viewsWatch on TikTok →

Quick answer

The video discusses three compounds, Dihexa, Semax, and guanfacine, as potential interventions for ADHD, focusing on prefrontal cortex neuroplasticity and neurotransmitter modulation. Guanfacine (Intuniv) is FDA-approved for pediatric ADHD and has an established pharmacological rationale, while Dihexa and Semax remain in preclinical or early research stages with no approved human indications. No compound discussed has been evaluated in a randomized controlled trial specifically for ADHD in adults.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Semax and selank for ADHD: what the brain peptide hype gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

ReviewSemax and selank evidence2020

Functional Connectomic Approach to Studying Selank and Semax Effects

Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.

PubMed

ReviewSemax and selank evidence2018

Effects of Semax on the Default Mode Network of the Brain

Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

Semax and selank for ADHD: what the brain peptide hype gets wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Semax and selank for ADHD: what the brain peptide hype gets wrong" from JonesX3. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video discusses three compounds, Dihexa, Semax, and guanfacine, as potential interventions for ADHD, focusing on prefrontal cortex neuroplasticity and neurotransmitter modulation.

The reason this review is not generic is the source wording and the canonical claim label "peptides replying to amazing question i wish i was a better talker bu." In this clip, the useful excerpt is: "To work stank and ADHD be subsided with peptides and all pharmaceuticals in general, and is it worth it?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Functional Connectomic Approach to Studying Selank and Semax Effects (2020), Effects of Semax on the Default Mode Network of the Brain (2018), and Therapeutic Peptides: Applications, Challenges, and Future Directions (2026), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Dihexa has only been tested in rodent models of cognitive impairment.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video discusses three compounds, Dihexa, Semax, and guanfacine, as potential interventions for ADHD, focusing on prefrontal cortex neuroplasticity and neurotransmitter modulation.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video discusses three compounds, Dihexa, Semax, and guanfacine, as potential interventions for ADHD, focusing on prefrontal cortex neuroplasticity and neurotransmitter modulation. Guanfacine (Intuniv) is FDA-approved for pediatric ADHD and has an established pharmacological rationale, while Dihexa and Semax remain in preclinical or early research stages with no approved human indications. No compound discussed has been evaluated in a randomized controlled trial specifically for ADHD in adults.
  • Guanfacine (Intuniv) is FDA-approved for ADHD in children aged 6-17 and has a well-documented alpha-2A adrenoceptor mechanism in the prefrontal cortex, per Arnsten et al. (2012, Neuropsychopharmacology).
  • Dihexa has only been tested in rodent models of cognitive impairment. McCoy et al. (2013) showed pro-cognitive effects in rats, but zero human clinical trials exist for any indication, including ADHD.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Guanfacine (Intuniv) is FDA-approved for ADHD in children aged 6-17 and has a well-documented alpha-2A adrenoceptor mechanism in the prefrontal cortex, per Arnsten et al. (2012, Neuropsychopharmacology).
  • Dihexa has only been tested in rodent models of cognitive impairment. McCoy et al. (2013) showed pro-cognitive effects in rats, but zero human clinical trials exist for any indication, including ADHD.
  • Semax's BDNF-upregulating effects are real in preclinical data (Dolotov et al., 2006), but translating rat hippocampus findings to human ADHD treatment is a major evidentiary leap that has not been made in any registered trial.
  • The claim that Dihexa can 'cure' ADHD symptoms is not supported by any published research. No peptide currently has regulatory approval for treating ADHD in any country.
  • Long-term stimulant use and cardiovascular risk is a legitimate clinical concern, but the framing that non-stimulant peptides are therefore safe alternatives ignores that Dihexa and Semax have no long-term human safety data at all.
  • Anecdotal exam performance improvements attributed to Semax cannot be used as evidence of cognitive enhancement — confounding factors like study habits, prior knowledge, and test difficulty are completely uncontrolled.
  • Anyone considering changes to an existing ADHD treatment plan should consult a licensed prescriber. Guanfacine requires titration and monitoring; Dihexa and Semax are not regulated medicines in most jurisdictions.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @fxe3_jones actually say?

The creator, who openly admits they're not a psychiatrist or neuroscientist, argued that peptides like Dihexa and Semax, along with the pharmaceutical guanfacine, could potentially "cure" ADHD symptoms. They claim Dihexa works through long-term potentiation mechanisms tied to HGF/c-Met receptor binding, that Semax boosts BDNF and modulates dopamine without stressing the sympathetic nervous system, and that guanfacine strengthens prefrontal cortex neural spines even under stress. They also anecdotally described someone who "took Semax before their 11th prelims and it improved their memory like crazy." To their credit, they flagged they're studying for the HSC, acknowledged they're not a medical professional, and told viewers not to take their advice. That disclaimer matters, because some of what follows is speculative at best.

Does the science back this up?

Partially, and unevenly across the three compounds. The Dihexa claims are the least supported in humans. The Semax and BDNF connection has real preclinical backing. Guanfacine is actually FDA-approved for ADHD in children. The problem is the creator blends solid mechanisms with significant overreach.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a hepatocyte growth factor mimetic studied primarily in rodents. McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics) showed it outperformed BDNF in reversing cognitive deficits in rats, but there are no published human trials. Calling it something that could help "cure" ADHD symptoms in humans is a significant leap from rat cognition data.

Semax's BDNF-upregulating effects are better documented. Dolotov et al. (2006, Journal of Molecular Neuroscience) confirmed BDNF and TrkB upregulation in rat hippocampus. The claim that it "modulates" rather than overstimulates dopaminergic systems is plausible, but human ADHD-specific trials are thin. The anecdote about exam performance proves nothing clinically.

Guanfacine is the strongest ground the creator stands on. Arnsten et al. (2012, Neuropsychopharmacology) established its alpha-2A adrenoceptor mechanism in the prefrontal cortex and its role in improving working memory and reducing distractibility. The signal-to-noise ratio framing they used is legitimately how researchers describe it.

What did they get wrong (or right)?

They got the guanfacine mechanism largely right. The alpha-2A postsynaptic agonism framing, the prefrontal cortex specificity, and the contrast with stimulant-driven norepinephrine release are all consistent with published pharmacology. Credit where it's due.

Where they went wrong: the claim that Dihexa can help "cure" ADHD symptoms is not supported by human data. Saying someone needs to "tire their brain" while on Dihexa to get results is entirely anecdotal and mechanistically unverified. The transcript also says you need to associate Dihexa "with complexity" to be "kind of cured" — this is not how synaptic plasticity research is framed in any peer-reviewed context.

The Semax exam anecdote is the weakest moment. One person scoring well after studying for an hour proves nothing. Confirmation bias, pre-existing ability, and test difficulty are all uncontrolled. Presenting it as evidence of cognitive enhancement is misleading for an audience that may be looking for shortcuts before exams.

  • Accurate: Guanfacine's prefrontal cortex mechanism and sympathetic nervous system sparing
  • Mostly accurate: Semax's BDNF and TrkB upregulation in preclinical models
  • Misleading: Dihexa framed as a near-cure for ADHD without human trial data
  • Inaccurate: Anecdote presented as evidence of cognitive enhancement

What should you actually know?

Dihexa and Semax are not approved by the FDA or TGA for ADHD or any cognitive condition. They are not regulated as medicines in most countries. Guanfacine is approved, but it's a prescription drug for a reason — dosing, monitoring, and drug interactions matter.

If you have ADHD and are considering anything beyond your current treatment plan, that conversation belongs with a prescriber who has your full medical history, not a TikTok video made by someone studying for their HSC. The creator's transparency about their qualifications is actually admirable for this platform, but that transparency also confirms why their recommendations should not be acted on.

The broader ADHD-peptide space is genuinely interesting to researchers. But "interesting to researchers" and "ready for self-administration" are separated by years of trials, safety data, and regulatory review. The mechanistic logic here is not entirely wrong. The confidence about outcomes is.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

JonesX3 · TikTok creator

4.4K views on this video

Replying to @ميسر Amazing question - I wish I was a better talker, but i’ve also been trying to study for my HSC so I hope this is worth your knowledge. This video is meant to be educational - I understand if it’s long and boring but for the people who are curious I hope this helps. Sharing my own experiences not just basic information #brain #edit #adhd #peptide #nootropics

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about guanfacine (intuniv)?

Guanfacine (Intuniv) is FDA-approved for ADHD in children aged 6-17 and has a well-documented alpha-2A adrenoceptor mechanism in the prefrontal cortex, per Arnsten et al. (2012, Neuropsychopharmacology).

What does the video say about dihexa has only been tested in rodent models of cognitive?

Dihexa has only been tested in rodent models of cognitive impairment. McCoy et al. (2013) showed pro-cognitive effects in rats, but zero human clinical trials exist for any indication, including ADHD.

What does the video say about semax's bdnf-upregulating effects?

Semax's BDNF-upregulating effects are real in preclinical data (Dolotov et al., 2006), but translating rat hippocampus findings to human ADHD treatment is a major evidentiary leap that has not been made in any registered trial.

What does the video say about the claim?

The claim that Dihexa can 'cure' ADHD symptoms is not supported by any published research. No peptide currently has regulatory approval for treating ADHD in any country.

What does the video say about long-term stimulant use?

Long-term stimulant use and cardiovascular risk is a legitimate clinical concern, but the framing that non-stimulant peptides are therefore safe alternatives ignores that Dihexa and Semax have no long-term human safety data at all.

What does the video say about anecdotal exam performance improvements attributed to semax cannot be used?

Anecdotal exam performance improvements attributed to Semax cannot be used as evidence of cognitive enhancement — confounding factors like study habits, prior knowledge, and test difficulty are completely uncontrolled.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by JonesX3, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.